The estimated Net Worth of Capital (Master), L.P.Sessa... is at least $470 Million dollars as of 14 April 2023. Capital Sessa owns over 2,190,549 units of Provention Bio stock worth over $388,876,075 and over the last 2 years Capital sold PRVB stock worth over $81,474,152.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Capital Sessa PRVB stock SEC Form 4 insiders trading
Capital has made over 2 trades of the Provention Bio stock since 2023, according to the Form 4 filled with the SEC. Most recently Capital sold 2,190,549 units of PRVB stock worth $53,274,152 on 14 April 2023.
The largest trade Capital's ever made was selling 3,000,000 units of Provention Bio stock on 18 January 2023 worth over $28,200,000. On average, Capital trades about 1,038,110 units every 17 days since 2023. As of 14 April 2023 Capital still owns at least 15,567,497 units of Provention Bio stock.
You can see the complete history of Capital Sessa stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Provention Bio
Over the last 5 years, insiders at Provention Bio have traded over $81,606,241 worth of Provention Bio stock and bought 165,475 units worth $1,543,065 . The most active insiders traders include Capital (Master), L.P.Sessa..., Nancy Wysenski, and Avery W Catlin. On average, Provention Bio executives and independent directors trade stock every 35 days with the average trade being worth of $3,621,900. The most recent stock trade was executed by Capital (Master), L.P.Sessa... on 14 April 2023, trading 2,190,549 units of PRVB stock currently worth $53,274,152.
What does Provention Bio do?
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
What does Provention Bio's logo look like?
Complete history of Capital Sessa stock trades at Provention Bio
Provention Bio executives and stock owners
Provention Bio executives and other stock owners filed with the SEC include:
-
Ashleigh Palmer,
President, Chief Executive Officer, Co-Founder, Director -
Eleanor Ramos,
Chief Medical Officer -
Francisco Leon,
Co-Founder, Chief Scientific Officer -
Andrew Drechsler,
Chief Financial Officer -
Ashleigh W. Palmer B.Sc., M.B.A.,
Co-Founder, Pres, CEO & Director -
Sean Doherty,
Independent Director -
Dr. Eleanor L. Ramos,
Chief Medical Officer -
Dr. Francisco Leon M.D., Ph.D.,
Co-Founder & Chief Scientific Officer -
Jason Hoitt,
Chief Commercial Officer -
Andrew T. Drechsler,
Special Advisor -
Francisco Leon M.D., Ph.D.,
Co-Founder & Chief Scientific Officer -
Jeffrey Bluestone,
Director -
Wayne Pisano,
Independent Chairman of the Board -
Avery Catlin,
Independent Director -
Sam Martin,
Investor Relations -
Nancy Wysenski,
Director -
John Jenkins,
Director -
Heidy King-Jones,
Chief Legal Officer -
Jason Hoitt,
Chief Commercial Officer -
Robert A. Doody Jr.,
VP of Investor Relations -
Christina Yi,
Chief Operations Officer -
Thierry Chauche,
Chief Financial Officer -
Dr. Sherron Kell,
Sr. VP of Clinical Devel. -
Heidy Abreu King-Jones J.D., L.L.M.,
Chief Legal Officer -
Justin Vogel,
Chief Accounting Officer -
Anthony Digiandomenico,
Director -
Miyoko Christina Yi,
Chief Operations Officer -
Benedict Osorio,
Chief Quality Officer -
Thierry Chauche,
Chief Financial Officer -
Rita Jain,
Director -
Sarah O'brien,
Chief People Officer -
Capital (Master), L.P.Sessa...,